Dashboard
Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 25.02%
- Healthy long term growth as Net Sales has grown by an annual rate of 46.50% and Operating profit at 42.29%
- Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.23 times
With a growth in Net Profit of 22.61%, the company declared Very Positive results in Sep 25
With ROCE of 23.7, it has a Very Expensive valuation with a 10.5 Enterprise value to Capital Employed
Increasing Participation by Institutional Investors
Stock DNA
Computers - Software & Consulting
INR 28,597 Cr (Small Cap)
59.00
NA
0.00%
0.24
21.69%
12.78
Total Returns (Price + Dividend) 
Inventurus Knowl for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Inventurus Knowl’s Evaluation Revised Amidst Mixed Market Signals
Inventurus Knowl, a small-cap player in the Computers - Software & Consulting sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment highlights evolving perspectives on the company’s quality, valuation, financial trends, and technical outlook amid recent market activity.
Read MoreWhy is Inventurus Knowl falling/rising?
As of 31-Oct, Inventurus Knowledge Solutions Ltd is experiencing a price increase, currently at 1,646.25, reflecting a rise of 79.7 points or 5.09%. Today's price summary indicates that the stock outperformed its sector by 5.73%, opened with a gain of 2.64%, and reached an intraday high of Rs 1680, marking a 7.24% increase. The stock has shown strong performance over the past week and month, with returns of +7.72% and +11.17%, respectively. Additionally, the company has demonstrated robust fundamentals, with a significant growth in net sales and profit, alongside a low debt-to-EBITDA ratio, which supports its strong long-term outlook. The increasing participation of institutional investors, who have raised their stake in the company, further bolsters confidence in its future performance. In the broader market context, while the Sensex has seen a slight decline of 0.32% over the past week, Inventurus Knowle...
Read MoreAre Inventurus Knowl latest results good or bad?
Inventurus Knowledge Solutions has reported strong financial results for the quarter ended September 2025, reflecting a continuation of its growth trajectory. The company achieved net sales of ₹781.09 crores, which represents a year-on-year growth of 21.52% and a sequential increase of 5.54%. This marks the highest quarterly revenue in the company's history, indicating robust client demand and effective operational execution. Net profit for the quarter reached ₹180.72 crores, showing a significant year-on-year increase of 59.93% and a quarter-on-quarter rise of 19.26%. The profit after tax (PAT) margin expanded to 23.14%, up from 17.58% in the same quarter last year, demonstrating the company's ability to convert revenue growth into profitability effectively. The operating margin also saw substantial improvement, reaching 34.79%, which is a notable increase from 29.42% in the corresponding quarter last ye...
Read More Announcements 
Announcement under Regulation 30 (LODR)-Press Release / Media Release
25-Nov-2025 | Source : BSEAttached herewith is Press Release titled IKS Health Expands Presence with the Launch of Its New Office in Coimbatore.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
17-Nov-2025 | Source : BSEIn terms of Regulation 30(6) read with Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you of the Schedule of the Analyst / Institutional Investor Meet of the Company as under: Day Date and Time: Friday November 21 2025 from 09:00 AM IST to 06:00 PM IST Name of the Conference: JM Financial India Conference Venue: The St. Regis Mumbai India Nature of Meet: Multiple investors During the said conference the investor presentation submitted to Stock Exchanges on October 30 2025 will be shared with multiple investors present during the conference. The said presentation is also available on the website of the Company at www.ikshealth.com. No Unpublished Price Sensitive Information will be shared at the said investor meet.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11-Nov-2025 | Source : BSEIn terms of Regulation 30(6) read with Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you of the Schedule of the Analyst / Institutional Investor Meet of the Company as under: Day Date and Time: Tuesday November 18 2025 from 09:00 AM IST to 06:00 PM IST Name of the Conference : Avendus Spark INDX: Annual Investor Conference Venue: Grand Hyatt BKC Mumbai India Nature of Meet: Multiple investors During the said conference the investor presentation submitted to Stock Exchanges on October 30 2025 will be shared with multiple investors present during the conference. The said presentation is also available on the website of the Company at www.ikshealth.com. No Unpublished Price Sensitive Information will be shared at the said investor meet.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 20 Schemes (2.26%)
Held by 77 FIIs (7.02%)
Aryaman Jhunjhunwala Discretionary Trust (16.37%)
Government Pension Fund Global (2.85%)
10.83%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 11.34% vs 10.02% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is 22.61% vs 13.09% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Nine Monthly Results Snapshot (Standalone) - Dec'24
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 11.50% vs 14.97% in Mar 2024
YoY Growth in year ended Mar 2025 is -1.47% vs 32.91% in Mar 2024






